Mitchell E. Levinson - 22 Mar 2022 Form 4 Insider Report for Pulse Biosciences, Inc. (PLSE)

Role
Chief Strategy Officer
Signature
/s/ Kenneth B. Stratton, as Attorney-in-Fact
Issuer symbol
PLSE
Transactions as of
22 Mar 2022
Net transactions value
$0
Form type
4
Filing time
24 Mar 2023, 16:30:32 UTC
Previous filing
20 Aug 2021
Next filing
10 Jun 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PLSE Stock Option (right to buy) Award +35,000 35,000 22 Mar 2023 Common Stock 35,000 $2.92 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on March 22, 2023 under the Issuer's 2017 Equity Incentive Plan. The shares subject to the option are subject to performance-based vesting criteria. 8,750 shares will vest in equal annual installments over the following four years on or about December 31, starting in 2023, subject to achievement of the vesting criteria and the reporting person's continued service through each vesting date.
F2 Not Applicable